Skip to main content
. Author manuscript; available in PMC: 2020 Feb 15.
Published in final edited form as: Int J Cardiol. 2018 Aug 7;277:212–219. doi: 10.1016/j.ijcard.2018.08.013

Figure 3. Validation of the prognostic role of plasma lncRNAs in patients with ESRD.

Figure 3

(A) Heat map and hierarchical clustering analysis of the expression levels of the 8 candidate plasma lncRNAs in an independent cohort of 111 study subjects (control 13, CKD 19, ESRD without CV event 43, ESRD with CV event 36). (B) Relative transcript expression levels of the 8 candidate lncRNAs in control, CKD and ESRD patients in the validation study cohort. (C) Univariate and multivariate analyses of candidate plasma lncRNAs linked to adverse CV outcomes in ESRD patients in the validation study cohort. #Combined index was derived from the combination of lncRNA DKFZP434I0714, KCNJ2AS1 and Dialysis Vintage (see methods). (D) Kaplan-Meier curve analysis showing significantly reduced survival in uremic patients with high plasma levels of lncRNA DKFZP434I0714 (>1.562 after normalized to the geometric mean of 4 reference genes). (D) Relative transcript expression levels of lncRNA DKFZP434I0714 in failing (HF, n=16) and non-failing (NF, n=8) human left ventricles (Human LV) and in human aortic endothelial cells (HAEC) exposed to hypoxic (1% O2, 5% CO2 for 24 and 48 hr, biological replicates, n=6 in each group) stress.